Filgrastim 300 µg
| Product Overview |
| Generic Name | Filgrastim 300 µg |
| Brand Name(s) | Neupogen |
| Form | Injection (IV/SC) Sol. |
| Strength | 300 µg/mL |
| Therapeutic Class | Hematopoietic agent (colony-stimulating factor) |
| ATC Code | L03AA02 |
| Manufacturing & Regulatory |
| Manufacturer | Amgen |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Biologics file BLA |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export |
| MOQ | 5 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Use and Indications for Filgrastim: Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) indicated to reduce the duration of neutropenia and the risk of infection in patients receiving myelosuppressive chemotherapy, undergoing bone marrow transplantation, or with severe chronic neutropenia. It stimulates the production and activation of neutrophils.
Request for Quote
